文献速递泌尿男性生殖肿瘤

卡博替尼联合纳武利尤单抗单用或联合伊匹木单抗治疗晚期/转移性泌尿生殖系统肿瘤的I期试验及扩展队列最终结果

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
PubMed 文献 · J Clin Oncol · 2024-07-02

这项研究者发起的多中心I期试验报告了卡博替尼联合纳武利尤单抗(CaboNivo)单用或联合伊匹木单抗(CaboNivoIpi)治疗晚期/转移性泌尿生殖系统肿瘤的最终分析,共纳入120例患者,中位随访49.2个月。在108例可评估患者中,客观缓解率为38%(完全缓解率11%),中位缓解持续时间20个月;CaboNivo组和CaboNivoIpi组≥3级治疗相关不良事件发生率分别为84%和80%。

要点

  • CaboNivo或CaboNivoIpi在多种泌尿生殖系统肿瘤中显示出临床活性和安全性。
  • 可评估患者总体客观缓解率38%,完全缓解率11%,中位缓解持续时间20个月。
  • ≥3级治疗相关不良事件发生率:CaboNivo组84%,CaboNivoIpi组80%。

核心结论

  • CaboNivo和CaboNivoIpi在多种泌尿生殖系统恶性肿瘤中显示出临床活性和安全性,尤其是透明细胞肾细胞癌、尿路上皮癌以及膀胱鳞状细胞癌、膀胱小细胞癌、膀胱腺癌、肾髓质癌和阴茎癌等罕见泌尿生殖系统肿瘤。

研究设计与样本

  • 研究者发起的多中心I期试验,包括剂量递增期和7个扩展队列,CaboNivo双药扩展队列包括转移性尿路上皮癌、转移性肾细胞癌和膀胱/脐尿管腺癌,CaboNivoIpi三药扩展队列包括转移性尿路上皮癌、转移性肾细胞癌、阴茎癌以及膀胱鳞状细胞癌和其他罕见泌尿生殖系统肿瘤(ClinicalTrials.gov标识:NCT02496208)。
  • 共纳入120例患者,接受CaboNivo(n=64)或CaboNivoIpi(n=56)治疗,中位随访49.2个月。

主要发现

  • 在108例可评估患者中(CaboNivo n=59;CaboNivoIpi n=49),客观缓解率为38%,完全缓解率为11%,中位缓解持续时间为20个月。
  • 客观缓解率:转移性尿路上皮癌为42.4%,转移性肾细胞癌为62.5%(n=16),膀胱鳞状细胞癌为85.7%(n=7),阴茎癌为44.4%(n=9),肾髓质癌为50.0%(n=2)。
  • ≥3级治疗相关不良事件发生率:CaboNivo组为84%,CaboNivoIpi组为80%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare genitourinary (GU) tumors in a dose-escalation phase I study. We report the final data analysis of the safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the phase I patients and seven expansion cohorts. METHODS: This is an investigator-initiated, multicenter, phase I trial. CaboNivo doublet expansion cohorts included (1) mUC, (2) mRCC, and (3) adenocarcinoma of the bladder/urachal; CaboNivoIpi triplet expansion cohorts included (1) mUC, (2) mRCC, (3) penile cancer, and (4) squamous cell carcinoma of the bladder and other rare GU tumors (ClinicalTrials.gov identifier: NCT02496208). RESULTS: The study enrolled 120 patients treated with CaboNivo (n = 64) or CaboNivoIpi (n = 56), with a median follow-up of 49.2 months. In 108 evaluable patients (CaboNivo n = 59; CaboNivoIpi n = 49), the ORR was 38% (complete response rate 11%) and the median duration of response was 20 months. The ORR was 42.4% for mUC, 62.5% for mRCC (n = 16), 85.7% for squamous cell carcinoma of the bladder (n = 7), 44.4% for penile cancer (n = 9), and 50.0% for renal medullary carcinoma (n = 2). Grade ≥ 3 treatment-related adverse events occurred in 84% of CaboNivo patients and 80% of CaboNivoIpi patients. CONCLUSION: CaboNivo and CaboNivoIpi demonstrated clinical activity and safety in patients with multiple GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of the bladder, renal medullary carcinoma, and penile cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Apolo AB, Girardi DM, Niglio SA, et al. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024. PMID: 38954785. doi:10.1200/JCO.23.02233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。